Lav-dosis Naltrexon til blæresmerter syndrom
Lav-dosis Naltrexon for blæresmerter syndrom: et randomiseret placebo-kontrolleret prospektivt pilotforsøg
Interstitiel blærebetændelse/blæresmertesyndrom (IC/PBS) er en konstellation af symptomer på bækkenubehag, der omfatter både blære-relateret smerte såvel som hyppighed af urinering, hastende og nocturia i fravær af en identificerbar ætiologi, der sandsynligvis påvirker mere end 5,4 mio. patienter i USA. Der er et betydeligt overlap hos patienter med IC/PBS og patienter med fibromyalgi og kronisk bækkensmertesyndrom. Lavdosis naltrexon (LDN) har vist sig at være effektiv til behandling af kroniske smertetilstande.
Det primære formål med denne undersøgelse er at evaluere, om LDN forbedrer smertescore og lavere urinvejssymptomer hos patienter med IC/PBS. Et sekundært mål er at vise, at det har en lav bivirkningsprofil.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Faktiske)
Tilmelding
Fase
Fase
- Fase 2
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Gabrielle Hettie
- Telefonnummer: 650-724-2091
- E-mail: bhettie@stanford.edu
Studiesteder
-
-
California
-
Stanford, California, Forenede Stater, 94304
- Stanford Health Care
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Beskrivelse
Inklusionskriterier:
- Mænd og kvinder med non-Hunner og Hunner læsionssygdom
- Opfyldelse af AUA-definitionen af BPS: En ubehagelig fornemmelse (smerte, tryk, ubehag), der opfattes som relateret til urinblæren forbundet med symptomer på nedre urinveje af mere end 6 ugers varighed i fravær af infektion eller anden identificerbar årsag.
- Stabil behandling i 1 måned
- 7-dages maksimum af smerte scorer mindst 4/10 på den numeriske vurderingsskala for smerter i blære/bækkenområdet. Urinfrekvens 8 eller højere, mens du er vågen. Nocturia 2 eller højere. BPIC-SS 19.
- Aftale om ikke at tage opioider under forsøgets varighed
Ekskluderingskriterier:
- Diagnose af stofbrugsforstyrrelser inklusive diagnose af opioidbrugsforstyrrelser
- Kendt allergi over for naltrexon eller naloxon
- Deltagelse i et andet klinisk forsøg
- Aktuel eller planlagt graviditet eller amning
- Kroniske smerter et andet sted i kroppen, der er mere alvorlige end det, der er relateret til BPS.
- Enhver intravesikal instillation inden for de sidste 8 uger
- Hvis på Elmiron, stabil dosis i de sidste 3 måneder
- Hvis på amitriptylin, stabil dosis i de sidste 3 måneder
- Enhver botox inden for de sidste 6 måneder
- Behandling for Hunners i de sidste 6 måneder
- Alle nye interstim-indstillinger inden for de seneste 3 måneder
- Enhver ny bækkenbundsfysioterapi inden for de sidste 12 uger
- Enhver ændring i eller ny håndkøbsmedicin i løbet af de sidste 2 måneder.
- Eventuelle smerteindgreb i de foregående 6 uger (epidural steroidinjektion, sympatisk blokering, perifer nerveblok, lumbale mediale grenblokke)
- Opioider kronisk for IC/BPS i fortiden, medmindre de har været slukket i 1 år
- Nylig kortvarig (inden for en uge efter tilmelding) opioidbrug for flairs
- Ingen dokumenteret cystoskopi i de sidste 5 år
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Aktiv komparator: Lavdosis naltrexon
4,5 mg naltrexon skal tages en time før sengetid hver nat i 8 uger.
|
4,5 mg tab (lavdosis) om natten
|
|
Placebo komparator: Placebo
Placebotablet (sukkerpille) skal tages en time før sengetid hver nat i 8 uger.
|
1 flig om natten
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The Numeric Rating Scale of Pain
Tidsramme: Will compare a 7-day average of pre-intervention Numeric Rating Scale of Pain scores to the 7-day average of post-intervention Numeric Rating Scale of Pain Scores after week 8 of treatment.
|
The Numeric Rating Scale (NRS) of Pain uses an 11-point likert scale.
Scores ranges from a minimum of 0 (No pain) to a maximum of 10 (Worst Pain Imaginable).
Higher scores indicate greater pain intensityThe proportion of subjects in the LDN and placebo groups that are responders with greater than 20% reductions in the worst daily Numeric Rating Scale of Pain scores after 8 weeks of treatment.
|
Will compare a 7-day average of pre-intervention Numeric Rating Scale of Pain scores to the 7-day average of post-intervention Numeric Rating Scale of Pain Scores after week 8 of treatment.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Brief Pain Inventory Score
Tidsramme: Comparing the average of 7 days of scores reported pre-intervention and the average of 7 days of score reported 8 weeks after intervention.
|
The Brief Pain Inventory score ranges from a minimum of 0 to a maximum of 10, with higher scores indicating worse pain intensity.
|
Comparing the average of 7 days of scores reported pre-intervention and the average of 7 days of score reported 8 weeks after intervention.
|
|
Voiding Diary
Tidsramme: Prior to treatment and after 8 weeks of treatment.
|
The Voiding Diary assesses the frequency and amount an individual voids over the course of a 24 hour period.
Study subjects indicate number of times they void in an hour and how much they urinate.
Study subjects complete daily voiding diaries over the course of a 7 day period before and after the intervention period.
Voiding frequency in a 24 hour period was assessed with possible range between 0 to 24 times per day.
Participants were asked to complete a 7-day voiding diary at baseline and after 8 weeks of treatment.
The average voiding frequency at baseline was compared to follow-up after 8 weeks of treatment.
|
Prior to treatment and after 8 weeks of treatment.
|
|
Change in Bladder Pain/Interstitial Cystitis Symptom Score
Tidsramme: At pre-intervention to week 8
|
Total score ranges from 0 to 38.
Higher values represent more symptoms of bladder pain associated with interstitial cystitis.
|
At pre-intervention to week 8
|
|
Change in O'Leary Sant Symptom Scores
Tidsramme: At pre-intervention to week 8
|
Scores range from 0-20 with higher scores representing more frequency of symptoms associated with interstitial cystitis such as urgency, frequency, nocturia (getting up at night to urinate), and pain or burning in the bladder.
|
At pre-intervention to week 8
|
|
Change in O'Leary Sant Problem Indices Scores
Tidsramme: At pre-intervention to week 8
|
Score ranges from 0 to 16 with higher scores representing that symptoms of interstitial cystitis are more problematic to the person with interstitial cystitis.
|
At pre-intervention to week 8
|
|
Change in Global Response Assessment Scale Score
Tidsramme: At pre-intervention to week 8
|
Patient-reported outcome measure.
7-point scale (ranging from markedly worse -3 to markedly improved +3), used to evaluate overall symptom change after treatment.
|
At pre-intervention to week 8
|
|
Change in PROMIS Pain Behavior Score
Tidsramme: At pre-intervention to week 8
|
Standardized metric (mean 50, standard deviation 10) assessing observable pain indicators, ranging from 20 to 80, with higher scores indicating more severe pain behavior.
|
At pre-intervention to week 8
|
|
Change in PROMIS Physical Function Score
Tidsramme: At pre-intervention to week 8
|
Standardized metric (mean 50, standard deviation 10) assessing self-reported capability, ranging from 20 to 80, with higher scores indicating better physical function
|
At pre-intervention to week 8
|
|
Change in PROMIS Sleep Dysfunction Score
Tidsramme: At pre-intervention to week 8
|
Standardized metric (mean 50, standard deviation 10) used to quantify self-reported sleep quality, depth, and restoration, ranging from 20 to 80, with a higher score indicating greater sleep disturbance.
|
At pre-intervention to week 8
|
|
Change in PROMIS Sleep-Related Impairment
Tidsramme: At pre-intervention to week 8
|
Sleep-related Impairment (SRI) score is a standardized, self-reported measure evaluating daytime alertness, sleepiness, and functional limitations over the past 7 days.
It uses a T-score metric (mean of 50, standard deviation of 10), where higher scores indicate greater impairment.
Scores range from 20-80.
|
At pre-intervention to week 8
|
|
Change in PROMIS Pain Interference Score
Tidsramme: At pre-intervention to week 8
|
The PROMIS Pain Interference (PI) score measures how much pain hinders a person's daily life-including physical, mental, emotional, and social activities-using a T-score metric where 50 is the average, and higher scores (e.g., 60+) indicate greater, more severe interference.
Scores range from 20-80
|
At pre-intervention to week 8
|
|
Change in PROMIS Fatigue Score
Tidsramme: At pre-intervention to week 8
|
The PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue score is a validated tool measuring the intensity, frequency, and impact of tiredness on daily life over the past seven days.
It uses a T-score metric (mean=50, SD=10) where higher scores (e.g., 60+) indicate greater, more severe fatigue.
Scores range from 20 to 80.
|
At pre-intervention to week 8
|
|
Change in PROMIS Anxiety Score
Tidsramme: At pre-intervention to week 8
|
Standardized metric (mean 50, standard deviation 10) assessing self-reported fear, anxious misery, and hyperarousal over the past 7 days, ranging from 20 to 80, with higher scores indicating more severe anxiety.
|
At pre-intervention to week 8
|
|
Change in PROMIS Depression Score
Tidsramme: At pre-intervention to week 8
|
Standardized metric (mean 50, standard deviation 10) assessing mood, self-view, and social cognition, ranging from 20 to 80, with higher scores indicating more severe depressive symptoms.
|
At pre-intervention to week 8
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Craig V Comiter, MD, Stanford University
- Ledende efterforsker: Phil Hanno, MD, Stanford University
- Ledende efterforsker: Jennifer M Hah, MD, MS, Stanford University
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Faktiske)
Primær færdiggørelse
Studieafslutning (Faktiske)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Mandlige urogenitale sygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Urinblæresygdomme
- Blærebetændelse
- Cystitis, Interstitiel
- Heterocykliske forbindelser
- Heterocykliske forbindelser, smeltet ring
- Alkaloider
- Polycykliske aromatiske kulbrinter
- Polycykliske forbindelser
- Heterocykliske forbindelser, 4 eller flere ringe
- Naloxon
- Morfinans
- Opiatalkaloider
- Heterocykliske forbindelser, bro-ring
- Fenanthrener
- Naltrexon
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 57305
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .